Navigation Links
German MedSys Project Adopts Genedata Phylosopher for Research Informatics
Date:4/27/2010

Genedata’s Target Discovery System Chosen as Central Data Management Solution for German Medical Systems Biology Initiative to Study Infectious Diseases of Fungal Pathogens.

(PRWEB) April 27, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Phylosopher has been adopted by the “Dr. Jekyll & Mr. Hyde” project, which is funded by the German Medical Systems Biology (MedSys) initiative. The multidisciplinary “Dr. Jekyll & Mr. Hyde” project, which is comprised of universities, research institutes, clinics, and industrial partners, aims at identifying novel targets for diagnostics, patient risk assessment, and therapy of infectious disease caused by the opportunistic fungal pathogen Candida albicans. Genedata Phylosopher will be the central data management infrastructure integrating and interpreting the high-throughput experimental data generated within the consortium, focusing on next-generation sequencing, microarray, proteome, and metabolite data.

“We decided to partner with Genedata because they offered a product-based solution for centralized data management,” explained Prof. U. Bilitewski, Dr. Jekyll & Mr. Hyde project coordinator at the Helmholtz Centre for Infection Research (Braunschweig, Germany). “Using Phylosopher we are able to perform –omics data and next-generation sequencing data integration and analysis in one system. This greatly helps us understand infection mechanisms of Candida.”

Candida albicans is the single most prevalent fungal pathogen causing up to 70% of all fungal hospital-acquired infections and is a major problem in intensive care units. While anti-mycotics are often given prophylactically to combat this problem, this leads to the selection of resistant strains requiring new therapeutic strategies. In the commensal state C. albicans asymptomatically colonize the host with the host protected from infection. Knowledge of molecular mechanisms, which prevent the pathogenicity of C. albicans, is still in its infancy. The “Dr. Jekyll and Mr. Hyde” project aims at identifying biomarkers that could guide a therapeutic intervention.

"The Dr. Jekyll & Mr. Hyde project is a network of excellent scientific institutions, and Genedata is proud to be part of this consortium,” said Dr. Othmar Pfannes, CEO of Genedata. “Having this interdisciplinary consortium chose Genedata Phylosopher as their central data management and analysis infrastructure demonstrates Genedata’s continued leadership in delivering tailored solutions based on a strong product portfolio and professional services for biomarker discovery for novel diagnostic and therapeutic approaches.”

About MedSys Initiative and Dr. Jekyll & Mr. Hyde Project
The “Dr. Jekyll and Mr. Hyde” project is granted within the German Medical Systems Biology program (www.fz-juelich.de/ptj/medsys). The project aims at generating a systems understanding of the key mechanisms leading to the protection of the host, i.e. preventing the pathogenic state of Candida albicans. The multidisciplinary consortium of universities, research institutes, clinics, and enterprises will focus on the study of host-pathogen interactions by assessing, from a Systems Biology perspective, both the response of the host to Candida albicans, and of this opportunistic pathogen to the host under commensal and pathogenic conditions.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher, Genedata Screener, Genedata Expressionist, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan, and the US. www.genedata.com.

###

Read the full story at http://www.prweb.com/releases/Genedata_MedSys/Systems_Biology/prweb3924104.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing?
2. Paternity Testing Without Father and Mother? The German Company bj-diagnostik Investigates that Two babies Separately Left at Charity Institution are Siblings
3. New silicon-germanium nanowires could lead to smaller, more powerful electronic devices
4. Health Robotics to Launch Germanys Installations of i.v.STATION(TM) at Charite-Universitatsmedizin Berlin
5. German Alliance for Industrial Biotechnology Debuts in Montreal
6. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
7. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
8. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
9. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
10. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
11. CPA Acquires Renowned German Patent Research Specialist, SVPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation ... leader commercializing its flagship CytoSorb® blood filter to ... patients around the world, announced that CEO Dr. ... at the Source Capital Group,s 2016 Disruptive Growth ... on the company.  Conference Presentation ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
Breaking Biology News(10 mins):